Project Details
Description
Narrative
Point mutations in cancers that are indicative of drug sensitivity or resistance are usually detected using
methods, such as PCR, that do not provide information about the distribution and the context of transformed
cells within healthy tissue. We are developing DNA probes that can identify mRNAs produced by the subtly
mutated genes in sections of cancer tissues in a particularly sensitive manner. Our approach would be
transformative for the clinical pathology practice, because it will become possible to develop digital maps of
classically stained tissue sections in which the information about molecular biomarkers indicative of the
success or failure of therapy is overlaid.
Status | Finished |
---|---|
Effective start/end date | 2/16/18 → 1/31/23 |
Funding
- National Cancer Institute: $557,328.00
- National Cancer Institute: $557,328.00
- National Cancer Institute: $501,595.00
- National Cancer Institute: $540,608.00
- National Cancer Institute: $557,328.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.